Literature DB >> 23759449

Six-month follow-up of a randomized controlled trial augmenting serotonin reuptake inhibitor treatment with exposure and ritual prevention for obsessive-compulsive disorder.

Edna B Foa1, Helen Blair Simpson, Michael R Liebowitz, Mark B Powers, David Rosenfield, Shawn P Cahill, Raphael Campeas, Martin Franklin, Chang-Gyu Hahn, Elizabeth A Hembree, Jonathan D Huppert, Andrew B Schmidt, Donna Vermes, Monnica T Williams.   

Abstract

OBJECTIVE: This article describes the long-term effects of augmenting serotonin reuptake inhibitors (SRIs) with exposure and ritual prevention or stress management training in patients with DSM-IV obsessive-compulsive disorder (OCD).
METHOD: Between November 2000 and November 2006, 111 OCD patients from 2 academic outpatient centers with partial SRI response were randomized to the addition of exposure and ritual prevention or stress management training, delivered twice weekly for 8 weeks (acute phase); 108 began treatment. Responders (38 of 52 in the exposure and ritual prevention condition, 11 of 52 in the stress management training condition) entered a 24-week maintenance phase. The Yale-Brown Obsessive Compulsive Scale (YBOCS) was the primary outcome measure.
RESULTS: After 24 weeks, patients randomized to and receiving exposure and ritual prevention versus stress management training had significantly better outcomes (mean YBOCS scores of 14.69 and 21.37, respectively; t = 2.88, P = .005), higher response rates (decrease in YBOCS scores ≥ 25%: 40.7% vs 9.3%, Fisher exact test P < .001), and higher rates of excellent response (YBOCS score ≤ 12: 24.1% vs 5.6%, Fisher exact test P = .01). During the maintenance phase, the slope of change in YBOCS scores was not significant in either condition (all P values ≥ .55), with no difference between exposure and ritual prevention and stress management training (P > .74). Better outcome was associated with baseline variables: lower YBOCS scores, higher quality of life, fewer comorbid Axis I diagnoses, and male sex.
CONCLUSIONS: Augmenting SRIs with exposure and ritual prevention versus stress management training leads to better outcome after acute treatment and 24 weeks later. Maintenance outcome, however, was primarily a function of OCD severity at entrance. Greater improvement during the acute phase influences how well patients maintain their gains, regardless of treatment condition. © Copyright 2013 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23759449      PMCID: PMC3977336          DOI: 10.4088/JCP.12m08017

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  18 in total

1.  The assessment of anxiety states by rating.

Authors:  M HAMILTON
Journal:  Br J Med Psychol       Date:  1959

2.  A rating scale for depression.

Authors:  M HAMILTON
Journal:  J Neurol Neurosurg Psychiatry       Date:  1960-02       Impact factor: 10.154

3.  The impact of depression on the treatment of obsessive-compulsive disorder: results from a 5-year follow-up.

Authors:  Gideon E Anholt; Idan M Aderka; Anton J L M van Balkom; Johannes H Smit; Haggai Hermesh; Els de Haan; Patricia van Oppen
Journal:  J Affect Disord       Date:  2011-09-01       Impact factor: 4.839

4.  Success and failure in the behavioral treatment of obsessive-compulsives.

Authors:  E B Foa; J B Grayson; G S Steketee; H G Doppelt; R M Turner; P R Latimer
Journal:  J Consult Clin Psychol       Date:  1983-04

5.  Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive-compulsive disorder.

Authors:  Edna B Foa; Michael R Liebowitz; Michael J Kozak; Sharon Davies; Rafael Campeas; Martin E Franklin; Jonathan D Huppert; Kevin Kjernisted; Vivienne Rowan; Andrew B Schmidt; H Blair Simpson; Xin Tu
Journal:  Am J Psychiatry       Date:  2005-01       Impact factor: 18.112

6.  Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure.

Authors:  J Endicott; J Nee; W Harrison; R Blumenthal
Journal:  Psychopharmacol Bull       Date:  1993

7.  The Yale-Brown Obsessive Compulsive Scale. II. Validity.

Authors:  W K Goodman; L H Price; S A Rasmussen; C Mazure; P Delgado; G R Heninger; D S Charney
Journal:  Arch Gen Psychiatry       Date:  1989-11

8.  Assessment of social adjustment by patient self-report.

Authors:  M M Weissman; S Bothwell
Journal:  Arch Gen Psychiatry       Date:  1976-09

9.  The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability.

Authors:  W K Goodman; L H Price; S A Rasmussen; C Mazure; R L Fleischmann; C L Hill; G R Heninger; D S Charney
Journal:  Arch Gen Psychiatry       Date:  1989-11

10.  The Obsessive-Compulsive Inventory: development and validation of a short version.

Authors:  Edna B Foa; Jonathan D Huppert; Susanne Leiberg; Robert Langner; Rafael Kichic; Greg Hajcak; Paul M Salkovskis
Journal:  Psychol Assess       Date:  2002-12
View more
  5 in total

1.  Cognitive behavioral therapy practices in the treatment of obsessive-compulsive disorder in China.

Authors:  Wenjuan Liu; Fang Fang; Chencheng Zhang; Eric A Storch
Journal:  Ann Transl Med       Date:  2017-01

2.  Change in obsessive-compulsive symptoms mediates subsequent change in depressive symptoms during exposure and response prevention.

Authors:  Laurie J Zandberg; Yinyin Zang; Carmen P McLean; Rebecca Yeh; Helen Blair Simpson; Edna B Foa
Journal:  Behav Res Ther       Date:  2015-03-13

3.  Six-month outcomes from a randomized trial augmenting serotonin reuptake inhibitors with exposure and response prevention or risperidone in adults with obsessive-compulsive disorder.

Authors:  Edna B Foa; Helen Blair Simpson; David Rosenfield; Michael R Liebowitz; Shawn P Cahill; Jonathan D Huppert; James Bender; Carmen P McLean; Michael J Maher; Raphael Campeas; Chang-Gyu Hahn; Patricia Imms; Anthony Pinto; Mark B Powers; Carolyn I Rodriguez; Page E Van Meter; Donna Vermes; Monnica T Williams
Journal:  J Clin Psychiatry       Date:  2015-04       Impact factor: 4.384

4.  Maximizing remission from cognitive-behavioral therapy in medicated adults with obsessive-compulsive disorder.

Authors:  Helen B Simpson; Edna B Foa; Michael G Wheaton; Thea Gallagher; Marina Gershkovich; Andrew B Schmidt; Jonathan D Huppert; Raphael B Campeas; Patricia A Imms; Shawn P Cahill; Christina DiChiara; Steven D Tsao; Anthony C Puliafico; Daniel Chazin; Anu Asnaani; Kelly Moore; Jeremy Tyler; Shari A Steinman; Arturo Sanchez-LaCay; Sandy Capaldi; Ivar Snorrason; Elizabeth Turk-Karan; Donna Vermes; Eyal Kalanthroff; Anthony Pinto; Chang-Gyu Hahn; Bin Xu; Page E Van Meter; Martha Katechis; Jennifer Scodes; Yuanjia Wang
Journal:  Behav Res Ther       Date:  2021-05-29

Review 5.  The study of active avoidance: A platform for discussion.

Authors:  Maria M Diehl; Christian Bravo-Rivera; Gregory J Quirk
Journal:  Neurosci Biobehav Rev       Date:  2019-09-08       Impact factor: 8.989

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.